A Phase III trial of SB-030 in the prevention of peripheral vein graft failure
Phase of Trial: Phase III
Latest Information Update: 29 May 2017
At a glance
- Drugs SB 030 (Primary)
- Indications Peripheral vascular disorders; Transplant rejection
- Focus Registrational; Therapeutic Use
- Sponsors Symic Bio
- 29 May 2017 New trial record
- 22 May 2017 According to a SYMIC Biomedical media release, the company anticipates initiating this trial in 2018.
- 22 May 2017 Based on a review of interim results from the SHIELD study (see profile 258965) in Type B pre-IND meeting, the FDA recommended proceeding with this trial as reported in a Symic Bio media release.